$FUL

FULLER H B CO (FUL): Results of Operations and Financial Condition

FULLER H B CO (FUL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_980922.htm EXHIBIT 99.1 ex_980922.htm Worldwide Headquarters 1200 Willow Lake Boulevard St. Paul, Minnesota 55110-5101 Exhibit 99.1 Scott Jensen Investor Relations Contact investors@hbfuller.com NEWS June 24, 2026 H.B. Fuller Reports Second Quarter 2026 Results Repor

Original reporting
Published Jun 25, 2026, 12:28 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 25, 2026, 12:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$FUL
Bullish
high confidence
Mentioned
$FUL
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$FULBullishHigh
01

Why it matters

The key tradable items are the Q2 performance metrics (revenue, margins, EPS/EBITDA, operating cash flow) and the updated FY ranges for adjusted EBITDA, adjusted EPS, and operating cash flow, plus the Q3 outlook ranges.

02

Market read

A guidance midpoint increase with record operating cash flow and margin expansion is a direct catalyst for repricing FUL’s FY earnings/FCF expectations.

03

What to watch

SG&A is up year-on-year (adjusted SG&A ~+3% excluding FX/variable comp), so traders should watch whether cost discipline holds in the second-half cash-flow-weighted period.

Relevance 7/10Novelty 9/10Timing: today’s SEC 8-K/earnings release; guidance update ahead of the June 25 conference call

Background

This is an SEC Form 8-K (Item 2.02) with the company’s Q2 2026 results and an update to fiscal 2026 guidance.

Company-level read

Ticker impact

$FULBullishHigh confidence
Context

H.B. Fuller reported Q2 results and raised full-year midpoint guidance for adjusted EBITDA and adjusted EPS, plus record operating cash flow.

Expected impact

Likely positive near-term reaction as traders reprice FY adjusted EBITDA/EPS and cash-flow durability; magnitude depends on how the new ranges compare to Street consensus.

Evidence & confidence

The filing is a primary earnings/guidance update with specific Q2 datapoints (EPS, EBITDA, margins, cash flow) and explicit FY outlook ranges updated upward at the midpoint.

Market effects

Signals resilience in industrial adhesives demand and pricing power, potentially supportive for peers’ margin expectations.

Limited direct regional read-through; company-specific execution and restructuring effects dominate.

Foreign currency and acquisition impacts are quantified, but the guidance update is primarily company-driven.

Counterpoint

Despite margin and cash-flow strength, net debt remains sizable (net debt-to-adjusted EBITDA 3.1X), so leverage optics could cap upside if credit conditions tighten.

Key entities

  • H.B. Fuller Company

    Adhesives manufacturer reporting Q2 2026 results and updating FY 2026 guidance in an SEC 8-K.

  • Celeste Mastin

    CEO quoted on execution, pricing actions, supply continuity, and the Quantum Leap restructuring initiative.

Related articles

$FULMedAI 8/10

H.B. Fuller board rejects unsolicited bid

H.B. Fuller's board rejected an unsolicited bid for its BAS segment, citing a valuation below market precedent and lack of financing details. The board highlighted BAS's 6% organic growth and 10% EBITDA improvement, noting its importance for future earnings. The board also cited operational integration challenges and reaffirmed its strategic priorities, including the Advanced Medical Solutions acquisition and Project Quantum Leap.

$FULMedAI 8/10

H.B. Fuller stock flat as board rejects Ancora’s adhesives bid

H.B. Fuller Co. (NYSE:FUL) shares were unchanged in premarket trading after its board rejected Ancora Holdings Group's $1.2 billion bid for its building adhesives unit, citing undervaluation and lack of growth potential consideration. Ancora criticized the rejection as irrational and emphasized its ability to finance a higher offer. The bid aimed to help H.B. Fuller reduce debt and focus on integrating Advanced Medical Solutions Group Plc.

$FULMed

AMS shareholders approve H.B. Fuller acquisition proposal

H.B. Fuller (NYSE:FUL) said Advanced Medical Solutions Group plc (LSE:AMS) shareholders approved the proposed cash acquisition of AMS. The approval is a milestone toward closing, which H.B. Fuller expects by year end, subject to remaining conditions and regulatory approvals. H.B. Fuller reported 2025 revenue of $3.5B.

$FULMed

Ancora offers up to $1.2bn for an H.B. Fuller business

Activist investor Ancora Holdings proposes an all-cash offer of up to $1.2bn to buy H.B. Fuller’s Building Adhesive Solutions unit, urging divestiture and offering to start due diligence. Ancora, holding over 2% of shares, says it has received no substantive response and may seek board control via a proxy fight. H.B. Fuller shares were down 2.3% intraday.

$FULMed

Why is H B Fuller stock sliding today?

H.B. Fuller shares fell about 1.3% after activist Ancora Holdings disclosed a formal cash offer to buy the company’s Building Adhesive Solutions segment for $1.1 billion to $1.2 billion, escalating a dispute over strategy. Separately, AMS shareholders approved H.B. Fuller’s recommended cash acquisition of Advanced Medical Solutions Group with 84.23% voting in favor. Macro CPI was in line.